Novel insights and innovations in targeting the neurohumoral system
Video navigation menu
- Current medication to improve morbidity/mortality in HFrEF 0:00
- PARADIGM-HF trial: LCZ696 compared with enalapril with respect to morbidity/mortality 0:37
- ATMOSPHERE trial - aliskiren compared with enalapril 1:42
- Potassium-binding drugs to lower hyperkalemia 2:19
- Conclusion - cornerstone drug therapy in HFrEF and new treatment modalities 3:11
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.